Innovative ETFs Content Hub Greater Regulatory Scrutiny Could Weigh on Biotech ETFs By Max ChenMarch 24, 2021
Beyond Basic Beta Content Hub Biotech Shined with Vaccines. It Can Do It Again with ‘BBH’ By Ben HernandezMarch 3, 2021
Innovative ETFs Content Hub Illumina Earnings, Forward Guidance Strengthen Biotech ETFs By Max ChenFebruary 12, 2021
Innovative ETFs Content Hub Biotechnology ETFs Soar on Biogen’s New Alzheimer’s Drug By Max ChenJanuary 29, 2021
Leveraged & Inverse Content Hub Up Over 100% in 2020 and 15% in 2021, ‘LABU’ Isn’t Holding Back By Ben HernandezJanuary 12, 2021
Thematic Investing Content Hub Can Global X’s GNOM Be the Next Big ETF? By Ben HernandezJanuary 11, 2021
Innovative ETFs Content Hub Consider Smaller Biotech ETFs as Big Pharma Goes Shopping in 2021 By Max ChenDecember 31, 2020
Thematic Investing Content Hub Get On Board a Growing Biotech Industry With the GNOM ETF By Ben HernandezDecember 23, 2020
Innovative ETFs Content Hub Biotech ETFs Tracking CRISPR Gene Editing Surge By Max ChenDecember 21, 2020
Webcasts America’s ‘Financial First Responders’ Examine the 2020 Election By Max ChenOctober 21, 2020
Nasdaq Investment Intelligence Content Hub Capitalizing on Today’s Tech: Semiconductors, AI, Robo and Internet Funds By Max ChenSeptember 8, 2020
Innovative ETFs Content Hub An Outperforming ETF for a Post-Coronavirus Pandemic World By Max ChenAugust 27, 2020
Webcasts A Targeted Biotech ETF to Access Next-Gen Healthcare Opportunities By Max ChenAugust 27, 2020
Multifactor Content Hub How to Gain Exposure to the Next Generation of Healthcare By Max ChenAugust 26, 2020
ETF of the Week ETF of the Week: Defiance Nasdaq Junior Biotechnology ETF (IBBJ) By Aaron NeuwirthAugust 20, 2020
Leveraged & Inverse Content Hub Biotech Has Been in a Steady Uptrend Even Through Covid-19 By Ben HernandezAugust 20, 2020
